A novel nanomicelle composed from PEGylated TB di-peptide could be successfully used as a BCG booster.
Nanovaccine
Nasal and parenteral – immunization
Recombinant fusion – peptide
Self-assembled – nanomicelles
Tuberculosis
Journal
Iranian journal of basic medical sciences
ISSN: 2008-3866
Titre abrégé: Iran J Basic Med Sci
Pays: Iran
ID NLM: 101517966
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
02
11
2021
accepted:
12
01
2022
entrez:
3
6
2022
pubmed:
4
6
2022
medline:
4
6
2022
Statut:
ppublish
Résumé
Tuberculosis affects one-third of the world's population and leads to a high rate of morbidity and mortality. Bacillus Chalmette-Guerin (BCG) as the only approved vaccine for the The main aim of this study was to prepare a self-assembled nanomicelle composed from a di-block polymer in which, a di-fusion peptide was the hydrophobic block and polyethylene glycol (PEG) was the hydrophilic block. The micelles were characterized The micellar nanovaccine was able to elicit good dendritic cell maturation. Nanomicelles could efficiently induce systemic cytokines as well as nasal secretory predominant antibody titers (sIgA). The expression pattern of cytokines indicated the superiority of cellular immunity. Nasal administration of two doses of nanomicelles after a prime subcutaneous administration of BCG induced the highest mucosal and systemic immune responses. Based on our results PEG-HspX/EsxS self-assembled nanomicelle is highly immunogenic and can be considered a potential vaccine candidate against
Identifiants
pubmed: 35655599
doi: 10.22038/IJBMS.2022.61373.13583
pmc: PMC9124544
doi:
Types de publication
Journal Article
Langues
eng
Pagination
223-231Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest relevant to this article.
Références
Pharmaceutics. 2019 Aug 01;11(8):
pubmed: 31374959
Iran J Pharm Res. 2019 Winter;18(1):446-458
pubmed: 31089379
Adv Drug Deliv Rev. 2005 Jan 10;57(3):333-55
pubmed: 15560945
Vaccine. 2014 Jan 9;32(3):327-37
pubmed: 24295808
Adv Drug Deliv Rev. 2018 Jan 15;124:125-139
pubmed: 28882703
Nat Rev Immunol. 2006 Feb;6(2):148-58
pubmed: 16491139
Iran J Basic Med Sci. 2020 Aug;23(8):1065-1077
pubmed: 32952954
Expert Rev Vaccines. 2018 Jan;17(1):31-44
pubmed: 29148853
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):370-377
pubmed: 30691310
Braz J Med Biol Res. 2012 Dec;45(12):1102-11
pubmed: 22948379
Nat Biomed Eng. 2018 May;2(5):318-325
pubmed: 30936455
Rep Biochem Mol Biol. 2018 Apr;6(2):125-130
pubmed: 29765994
Front Immunol. 2019 Nov 29;10:2807
pubmed: 31849981
Chem Soc Rev. 2009 Feb;38(2):606-31
pubmed: 19169468
Front Immunol. 2014 Apr 07;5:152
pubmed: 24778634
Artif Cells Nanomed Biotechnol. 2017 Mar;45(2):291-296
pubmed: 26924121
Front Immunol. 2018 Oct 04;9:2224
pubmed: 30337923
Front Immunol. 2018 Oct 16;9:2371
pubmed: 30386336
Infect Immun. 2007 Jun;75(6):2914-21
pubmed: 17387166
J Immunol Res. 2015;2015:639107
pubmed: 26495323
Microb Pathog. 2018 Dec;125:507-513
pubmed: 30352265
Front Immunol. 2017 Mar 27;8:327
pubmed: 28396662
Vaccine. 2011 Jan 29;29(5):1045-52
pubmed: 21129393
J Mater Sci Mater Med. 2010 Jul;21(7):2027-34
pubmed: 20379764
Vaccine. 2014 May 30;32(26):3162-8
pubmed: 24726245
Eur J Pharm Biopharm. 2019 Sep;142:232-239
pubmed: 31229673
Vaccine. 2020 Jul 31;38(35):5665-5677
pubmed: 32653275
Pharmaceutics. 2020 May 28;12(6):
pubmed: 32481601
Semin Immunopathol. 2020 Jun;42(3):315-331
pubmed: 32189035
Vaccines (Basel). 2020 Oct 05;8(4):
pubmed: 33027958
Infect Immun. 2002 Feb;70(2):672-8
pubmed: 11796598
Immunology. 2018 Mar;153(3):325-336
pubmed: 28881482
PLoS Pathog. 2012;8(5):e1002607
pubmed: 22589713
Cell Mol Immunol. 2018 Mar;15(3):216-225
pubmed: 29176747
Parasitol Res. 2011 May;108(5):1265-73
pubmed: 21125294
Braz J Infect Dis. 2017 Mar - Apr;21(2):155-161
pubmed: 27932286
Vaccine. 2015 Nov 27;33(48):6800-8
pubmed: 26478198
Cytokine Growth Factor Rev. 2010 Dec;21(6):455-62
pubmed: 21075039
Eur Respir J. 2019 Sep 12;54(3):
pubmed: 31221810